Financial

Jefferies Remains Positive On NUVA, Lowers PT To $34 From $36

Despite near-term challenges and uncertainty in the spine market, Jefferies said that it remains positive on the NuVasive, Inc. (NASDAQNUVA) story and believe the stock should reward long-term investors.

“We rate the shares Buy,” Jefferies writes. “NUVA released preliminary earnings this evening exceeding guidance for 2010 and narrowed 2011 revenue guidance to 10-12% from 10-20%. The company is presenting at an investor conference on Tuesday and should provide further detail.”

Jefferies has lowered its PT on NuVasive to $34 from $36.

NuVasive closed Monday at $26.44.

Read more: http://www.benzinga.com/analyst-ratings/11/01/769540/jefferies-remains-positive-on-nuva-raises-pt-to-36-from-34#ixzz1AkQuP6hF

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button